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Background: The present study aimed to evaluate the indications for a second prostate biopsy in
patients suspected with prostate cancer after an initial negative prostate biopsy.
Methods: The present study included 421 patients who underwent repeat prostate biopsy between
January 2007 and December 2015 at three hospitals. Clinicopathological data, including patient age, body
mass index, history of prostate biopsy, prostate volume, prostate-speciﬁc antigen (PSA) level, PSA den-
sity, PSA velocity, and PSA ﬂuctuation patterns, were analyzed. The patients were stratiﬁed into two
groups based on the ﬁrst PSA pattern (increase/decrease) within 1 year after the initial negative prostate
biopsy.
Results: Prostate cancer was detected in 100 (23.8%) of the 421 patients at the second prostate biopsy. In
patients with a PSA decrease at the ﬁrst follow-up, prostate volume and number of increases in the PSA
level from the initial prostate biopsy were predictors for prostate cancer diagnosis at the second prostate
biopsy. In patients with a steady PSA increase after the initial prostate biopsy, prostate volume and
number of biopsy cores were predictors for prostate cancer diagnosis at the second prostate biopsy.
Conclusion: The indications for a second prostate biopsy are a low prostate volume and a high number
of increases in the PSA level among patients with a PSA decrease at the ﬁrst follow-up and a low prostate
volume and a high number of biopsy cores among patients with a PSA increase at the ﬁrst follow-up.
© 2017 Asian Paciﬁc Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The only diagnostic method for conﬁrming prostate cancer
(PCa) is prostate biopsy. Prostate-speciﬁc antigen (PSA) is the most
novel serum marker used for the early detection and management
of PCa.1,2 However, PSA testing involves some issues owing to the
relative lack of cancer speciﬁcity.3 Moreover, in a previous study,
approximately 20e30% of patients with potential PCa were not
identiﬁed at the ﬁrst prostate biopsy.4 Appropriate interpretation of
PSA ﬁndings is necessary after an initial negative biopsy, and the
interpretation can be complex in patients suspected with PCa, suchUrological Science Institute,
Gangnam-gu, Seoul 135-720,
te Society, Published by Elsevieras those with abnormal digital rectal examination (DRE) ﬁndings, a
high PSA level, and pathological ﬁndings at the initial biopsy. The
use of various imaging-guided biopsy approaches, including
Doppler-targeted biopsy protocols, contrast-enhanced ultrasound,
sonoelastography, and multiparametric prostate magnetic reso-
nance imaging (mpMRI) has increased the cancer detection rate.
With regard to concerns about overdiagnosis and overtreatment of
PCa related to cost effectiveness, most urologists select methods
involving a high number of biopsy cores and additional targeted
biopsy.5
The National Comprehensive Cancer Network (NCCN) guide-
lines recommend that patients with an initial negative biopsy
result should undergo PSA assessment and DRE at 1-year intervals
initially and then undergo a repeat biopsy based on risk stratiﬁ-
cation and/or the results of biomarkers that have high speciﬁcity,
such as prostate health index, Prostate CAncer gene 3 (PCA3) andKorea LLC. This is an open access article under the CC BY-NC-ND license (http://
Lee et al / Indications for a second prostate biopsy 25free/total prostate-speciﬁc antigen ratio (%fPSA).6 No deﬁnite in-
dications for the second prostate biopsy have been identiﬁed, and
the time to use additional approaches, such as biomarker assess-
ment, mpMRI-targeted biopsy, and saturation biopsy, is unclear.
The aim of the present study was to evaluate the indication for a
second prostate biopsy in patients suspected with PCa after an
initial negative prostate biopsy.
2. Materials and methods
A total of 9,908 patients underwent prostate biopsy at three
hospitals [Sinchon Severance Hospital (n ¼ 5,567), Gangnam
Severance Hospital (n ¼ 2,063), and National Health Insurance
Service Ilsan Hospital (n ¼ 2278)] between January 2007 and
December 2015. The reason for the initial prostate biopsy was a
high PSA level of  3 ng/mL. Of the 6,737 patients whose initial
biopsy result was negative, 527 consecutive patients initially un-
derwent 12-core to 14-core prostate biopsy, with negative results,
and then underwent a second prostate biopsy because of a high risk
of PCa. The risk factors included prior high-grade prostatic intra-
epithelial neoplasia or atypical small acinar proliferation of the
prostate, evaluation of biochemical failure after deﬁnitive treat-
ment, such as prostatectomy and radiotherapy, an increase in the
PSA level during follow-up, and abnormal DRE ﬁndings. Patients
with a previous diagnosis of PCa, a history of receiving 5-alpha
reductase inhibitors, a history of transurethral resection of the
prostate, a pathological diagnosis of prostatic intraepithelial
neoplasia or atypical small acinar proliferation, or a history of un-
dergoing various imaging-guided biopsies before repeat prostate
biopsy were excluded from the study cohort. Finally, 421 patients
were included in the analysis. PSA follow-up after the initial
negative biopsy was performed every 3e6 months.
Clinicopathological data, including patient age, body mass in-
dex, history of prostate biopsy, prostate volume, PSA level, PSA
density, PSA velocity (PSAV), and PSA ﬂuctuation patterns, were
analyzed using our computerized database. PSAV was calculated as
the PSA level at one time point minus the PSA level at another time
point divided by the time elapsed in years between these two
measurements. The patients were stratiﬁed into two groups based
on the ﬁrst PSA pattern (increase/decrease) within 1 year after the
initial negative prostate biopsy.
This retrospective study was performed in accordance with
the Institutional Review Board practice guidelines. ContinuousTable 1
Baseline patient characteristics.
Tota
No. of patients 421
Age at initial PBx (yr) 66.1 ± 8
PSA at initial PBx (ng/mL) 8.90 ± 7
PSA at repeat PBx (ng/mL) 10.01 ±
Prostate volume (cc) 47.62 ±
PSA density at initial PBx (ng/mL/cc) 0.20 ± 0
PSA density at repeat PBx (ng/mL/cc) 0.23 ± 0
No. of PBx core (n) 13.34 ±
No. of PSA down at the ﬁrst follow up after initial PBx 106 (25.
Levels of PSA down at the ﬁrst follow up after initial PBx (ng/mL) 0.15 ± 0
PSAV before the initial PBx (ng/mL/yr) 0.56 ± 2
PSAV before the repeat PBx (ng/mL/yr) 0.31 ± 2
PSAV between the initial and repeat PBx (ng/mL/yr) 4.51 ± 3
Average of PSA levels before the initial PBx (ng/mL) 8.76 ± 7
Standard deviation of PSA levels before the initial PBx (ng/mL) 3.20 ± 6
Average of PSA levels for the follow-up duration (ng/mL) 9.26 ± 6
Standard deviation of PSA levels for the follow-up duration (ng/mL) 2.73 ± 4
Average of PSA levels after the repeat PBx (ng/mL) 7.29 ± 6
Standard deviation of PSA levels after the repeat PBx (ng/mL) 2.93 ± 6
Data are presented as n (%) or mean ± SD.
PBx, prostate biopsy; PSA, prostate cancer-speciﬁc antigen; PSAV, PSA velocity.variables are expressed as mean ± standard deviation, and cate-
gorical variables are expressed as number of occurrences and fre-
quency. Student's t test was used for statistical comparisons of the
continuous and categorical variables. Additionally, simple and
multiple logistic regression analyses were performed. All statistical
analyses were performed using SPSS version 21 (IBM Corporation,
Armonk, NY, USA). A P value of < 0.05 was considered statistically
signiﬁcant.
3. Results
The baseline characteristics of the cohort are presented in
Table 1. The mean age of the patients was 66.1 years, and the mean
PSA levels before the initial and second biopsies were 8.90 ng/mL
and 10.01 ng/mL, respectively. The mean time from the initial bi-
opsy to the second biopsy was 25.6 months, and the mean follow-
up duration for PSA screening before PCa detection was 48.5
months. Among the 421 patients, 100 (23.8%) were diagnosed with
PCa at the second prostate biopsy. There were no statistically sig-
niﬁcant differences in the PSA levels at the initial and second
biopsies between patients with PCA and those without PCa at the
second prostate biopsy (P ¼ 0.533 and P ¼ 0.426, respectively).
However, the prostate volume, PSA densities at the initial and
second biopsies, and number of prostate biopsy cores were higher
in patients with PCa than in those without PCa at the second
prostate biopsy (prostate volume: 38.16 cc vs. 50.66 cc, P < 0.001;
PSA densities: 0.24 ng/mL/cc vs. 0.19 ng/mL/cc, P < 0.024 and
0.29 ng/mL/cc vs. 0.22 ng/mL/cc, P < 0.016; number of prostate
biopsy cores: 14.24 vs. 13.06, P ¼ 0.039, respectively).
Multivariate analysis showed that age [hazard ratio (HR) ¼ 1.06,
95% conﬁdence interval (CI) ¼ 1.021e1.101, P ¼ 0.003), prostate
volume (HR ¼ 0.97, 95% CI ¼ 0.950e0.985, P < 0.001), number of
prostate biopsy cores ( 13 vs.12; HR ¼ 2.56, 95% CI ¼ 1.332e4.926,
P ¼ 0.005), number of increases in the PSA level at the time from
before the time for the duration between the initial and repeat
biopsy (1 vs. 0; HR ¼ 3.56, 95% CI ¼ 1.385e9.167, P ¼ 0.008) were
the predictive factors for a positive biopsy (Table 2).
On comparing the groups based on the ﬁrst PSA pattern (in-
crease/decrease) within 1 year after the initial negative prostate
biopsy, we noted that the PSA level at the initial prostate biopsywas
lower, the PSA density at the initial prostate biopsy was lower, the
mean PSA level before the initial prostate biopsy was lower, the
mean PSA level for the duration between the initial and secondl Prostate cancer (þ) Prostate cancer () P
100 (23.8) 321 (76.2)
.1 67.9 ± 7.3 65.5 ± 8.29 0.009
.13 8.46 ± 6.51 9.04 ± 7.32 0.533
8.77 10.67 ± 10.13 9.80 ± 8.31 0.426
22.94 38.16 ± 16.32 50.66 ± 23.94 < 0.001
.14 0.24 ± 0.18 0.19 ± 0.12 0.024
.23 0.29 ± 0.24 0.22 ± 0.17 0.016
4.42 14.24 ± 5.18 13.06 ± 0.41 0.039
2) 29 (29.0) 77 (24.0) 0.849
.91 1.58 ± 9.05 0.68 ± 9.07 0.073
7.15 2.88 ± 15.31 0.06 ± 29.55 0.619
5.68 3.17 ± 48.52 1.41 ± 11.28 0.461
4.94 8.93 ± 44.78 3.11 ± 31.21 0.258
.38 8.65 ± 7.94 8.80 ± 7.21 0.875
.53 1.85 ± 3.23 3.66 ± 7.25 0.008
.75 9.37 ± 7.41 9.22 ± 6.54 0.866
.31 2.52 ± 4.47 2.79 ± 4.26 0.656
.55 7.29 ± 6.55 0.812
.32 2.93 ± 6.32 0.842
Table 2
Univariate and multivariate logistic regression analyses for predictors of the presence of prostate cancer at the second prostate biopsy.
Univariate Multivariate
HR 95% CI P HR 95% CI P
Age at initial PBx* 1.04 1.009 1.070 0.010 1.06 1.021 1.101 0.003
PSA at initial PBx* 0.99 0.952 1.031 0.650
PSA at repeat PBx* 1.01 0.984 1.037 0.450
Prostate volume* 0.97 0.950 0.980 < 0.001 0.97 0.950 0.985 < 0.001
No. of PBx core (13 vs. 12) 1.83 1.096 3.044 0.021 2.56 1.332 4.926 0.005
No. of PSA decrease at the ﬁrst follow-up after initial PBx* 1.51 0.817 2.778 0.189
Levels of PSA decrease at the ﬁrst follow-up after initial PBx* 1.01 0.958 1.063 0.741
PSAV before the initial PBx* 0.99 0.952 1.031 0.650
PSAV before the repeat PBx* 1.00 0.996 1.012 0.296
PSAV between the initial and repeat prostate biopsy* 1.00 0.995 1.003 0.648
Average of PSA levels before the initial PBx* 1.00 0.982 1.019 0.978
Standard deviation of PSA levels before the initial PBx* 0.94 0.868 1.018 0.130
Average of PSA levels for the follow-up duration* 0.94 0.853 1.038 0.225
Standard deviation of PSA levels for the follow-up duration* 1.02 0.975 1.056 0.469
No. of PSA increase from the initial PBx before the repeat
biopsy ( 4 vs. 0e3)
1.87 1.008 3.460 0.047 1.33 0.665 2.654 0.421
No. of PSA increase at the time from before the time for the
follow-up duration ( 1 vs. 0)
3.41 1.287 9.015 0.014 3.56 1.385 9.167 0.008
*, Continous variable.
CI, conﬁdence interval; HR, hazard ration; PBx, prostate biopsy; PSA, prostate cancer-speciﬁc antigen; PSAV, PSA velocity.
Prostate Int 5 (2017) 24e2826prostate biopsies was higher, and the standard deviation of the PSA
level for the duration between the initial and second prostate bi-
opsies was lower in the group that showed a PSA decrease than in
the group that showed a PSA increase (P < 0.001, P < 0.001,
P ¼ 0.026, P < 0.001, and P < 0.001, respectively; Table 3).
In multivariate analysis of patients with a PSA decrease at the
ﬁrst follow-up after the initial prostate biopsy, prostate volume
(HR ¼ 0.96, P ¼ 0.006) and number of increases in the PSA level
from the initial prostate biopsy before the repeat biopsy ( 2 vs.
0e1) (HR ¼ 3.21, P ¼ 0.031) were signiﬁcant predictors of the
diagnosis of PCa at the second prostate biopsy (Table 4). Addi-
tionally, in multivariate analysis of patients with a steady PSA in-
crease at the ﬁrst follow-up after the initial prostate biopsy,
prostate volume (HR ¼ 0.95, P ¼ 0.12) and number of prostate bi-
opsy cores ( 13 vs. 12; HR ¼ 4.34, P ¼ 0.008) were signiﬁcant
predictors of the diagnosis of PCa at the second prostate biopsy
(Table 4).Table 3
Characteristics of the patients stratiﬁed into two groups based on the ﬁrst prostate-speciﬁ
biopsy.
PSA decrea
after initial
No. of patients
Age at initial PBx (yr)
PSA at initial PBx (ng/mL)
PSA at repeat PBx (ng/mL)
Prostate volume (cc)
PSA density at initial PBx (ng/mL/cc)
PSA density at repeat PBx (ng/mL/cc)
No. of PBx core (n)
Levels of PSA decrease at the ﬁrst follow-up after initial PBx (ng/mL)
PSAV before the initial PBx (ng/mL/yr) 
PSAV before the repeat PBx (ng/mL/yr)
PSAV between the initial and repeat PBx (ng/mL/yr)
Average of PSA levels before the initial PBx (ng/mL)
Standard deviation of PSA levels before the initial PBx (ng/mL)
Average of PSA levels for the follow-up duration (ng/mL)
Standard deviation of PSA levels for the follow-up duration (ng/mL)
Average of PSA levels after the repeat PBx (ng/mL)
Standard deviation of PSA levels after the repeat PBx (ng/mL)
Data are presented as n (%) or mean ± SD.
PBx, prostate biopsy; PSA, prostate cancer-speciﬁc antigen; PSAV, PSA velocity.4. Discussion
For patients with an initial negative prostate biopsy, the second
prostate biopsy should be considered when there are persistent
clinical indications of PCa, such as a steady increase in the PSA level
and abnormal DRE ﬁndings. We found that old age, low prostate
volume, high number of prostate biopsy cores, and one more time
of increase PSA at the time compared to before the time are useful
for predicting PCa. For patients with a decrease in the PSA level
after the initial prostate biopsy, the second prostate biopsy was
recommended at the second instance (or further instances) of a PSA
level higher than that at the initial prostate biopsy, and a high
number of biopsy cores had no beneﬁt for the detection of PCa. For
patients with a steady increase in the PSA level after the initial
prostate biopsy, a high number of biopsy cores could predict PCa.
Prostate biopsy is the only diagnostic method to conﬁrm PCa.
However, 20e30% of the cases of PCa might be missed at the initialc antigen pattern (increase/decrease) within 1 year after an initial negative prostate
se at the ﬁrst follow-up
prostate biopsy (n ¼ 106)
PSA increase at the ﬁrst follow-up
after initial prostate biopsy (n ¼ 125)
P
29 (27.4) 25 (20.0) 0.849
65.50 ± 8.72 66.39 ± 7.55 0.854
7.10 ± 4.74 10.67 ± 8.35 < 0.001
10.12 ± 7.47 10.06 ± 9.67 < 0.001
44.67 ± 18.37 53.11 ± 25.23 0.892
0.18 ± 0.13 0.22 ± 0.15 < 0.001
0.25 ± 0.19 0.21 ± 0.18 < 0.001
13.16 ± 3.57 12.92 ± 3.19 0.898
2.56 ± 3.57 3.77 ± 6.68 < 0.001
12.16 ± 61.13 5.69 ± 63.03 0.003
0.72 ± 20.94 21.77 ± 199.58 0.234
5.92 ± 12.28 0.25 ± 13.17 < 0.001
7.84 ± 5.41 9.95 ± 9.09 0.026
2.82 ± 4.20 4.93 ± 9.28 0.176
9.39 ± 6.46 8.47 ± 5.83 < 0.001
2.52 ± 2.78 2.63 ± 5.10 < 0.001
5.35 ± 2.55 7.68 ± 4.44 0.112
1.29 ± 1.69 4.08 ± 6.34 0.146
Table 4
Univariate and multivariate logistic regression analyses for predictors of prostate cancer based on the ﬁrst prostate-speciﬁc antigen pattern (increase/decrease) within 1 year
after an initial negative prostate biopsy.
PSA decrease at the ﬁrst follow-up after initial PBx PSA increase at the ﬁrst follow-up after initial PBx
Univariate Multivariate Univariate Multivariate
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age at initial PBx* 1.00 0.944 1.057 0.968 1.04 0.992 1.098 0.102
PSA at initial PBx* 0.93 0.857 1.012 0.093 1.08 0.987 1.174 0.095
PSA at repeat PBx* 0.98 0.929 1.038 0.522 1.04 0.982 1.090 0.202
Prostate volume* 0.96 0.935 0.987 0.004 0.96 0.938 0.989 0.006 0.96 0.926 0.992 0.016 0.95 0.917 0.989 0.012
No. of PBx core ( 13 vs. 12) 3.77 1.145 12.385 0.029 2.82 0.711 11.215 0.140 3.46 1.280 9.327 0.014 4.34 1.465 12.859 0.008
PSAV before the initial PBx* 1.00 0.989 1.020 0.585 1.01 0.995 1.017 0.328
PSAV before the repeat PBx* 1.00 0.993 1.005 0.671 1.00 0.977 1.015 0.660
PSAV between the initial and repeat PBx* 1.00 0.974 1.035 0.789 1.01 0.983 1.047 0.380
No. of PSA increase from the initial PBx before
the repeat biopsy ( 4 vs. 0e3)
3.00 0.799 11.263 0.104 1.99 0.776 5.125 0.152
No. of PSA increase from the initial PBx before
the repeat biopsy ( 2 vs. 0e1)
3.31 1.254 8.736 0.016 3.21 1.114 9.227 0.031 1.28 0.528 3.112 0.583
*, Continous variable.
CI, conﬁdence interval; HR, hazard ration; PBx, prostate biopsy; PSA, prostate cancer-speciﬁc antigen; PSAV, PSA velocity.
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decrease with repeat biopsies (34% for the ﬁrst biopsy, 25% for the
second, and 24% for the third).7 For patients who underwent a
second prostate biopsy, the PCa detection rate was similar between
the present study (23.8%) and this previous study.
The concept of PSAV suggested by Carter et al8 has been widely
used.8 Several studies have reported regarding the beneﬁts of using
PSAV.9 A previous study reported that PSAV (cutoff value: 0.75 ng/
mL/y) helped to identifymenwith PCa.10 Ulmert et al11 showed that
PSAV alone could signiﬁcantly detect PCa onmultivariate analysis.11
However, these results are not consistent with those of our study
among patients who underwent a second prostate biopsy. We
found that the PSAV between the initial and second prostate bi-
opsies was not a predictor of PCa (P ¼ 0.648).
Several clinicians experienced difﬁculty in reproducing results
with 1- and 2-year intervals between PSA assessments because PSA
assessments were performed with intervals of several years and
patients showed ﬂuctuating PSA values (increases and decreases).12
The deﬁnition of PSA ﬂuctuation was not consistent in previous
studies, and the effect of PSA ﬂuctuation on the detection of PCa
remains controversial. Previous studies have reported that there
was no statistically signiﬁcant difference in the positive rate of
repeat biopsy between patients with ﬂuctuating PSA levels and
those with steadily increasing PSA levels.12,13 However, Park et al14
analyzed 492 patients who underwent repeat prostate biopsy and
reported that the PSA ﬂuctuation patternwas a signiﬁcant predictor
of a positive repeat biopsy.14 When PSA ﬂuctuation was considered
according to the number of increases in the PSA level at the time
from before the time for the duration between the initial and sec-
ond prostate biopsy, the detection rate of PCa was signiﬁcantly
higher in the group with ﬂuctuating PSA levels than in the group
with steadily increasing PSA levels (25.5% vs. 10.3%, P ¼ 0.010).
Previous studies have evaluated the relation between PSA
variation and PCa. In a previous study that evaluated 64 men, the
coefﬁcient of variation, calculated by dividing the standard devia-
tion of each set of serum PSA levels by the mean of the levels and
multiplying by 100, was used as a parameter that reﬂected the
intra-individual variability of PSA.15 The coefﬁcient of variation has
been reported to be lower in patients with cancer than in those
without cancer (5.7% vs. 9.7%). In our study, the mean and standard
deviation of the PSA levels for the duration between the initial and
repeat prostate biopsies had no inﬂuence on the diagnosis of PCa.
The coefﬁcient of variation determined by obtaining two or more
PSA values over a period of 4 weeks is similar to that in the priorstudy in part of only higher in without PCa than with PCa (27.1% vs.
25.4%, P ¼ 0.619). However, the number of patients was low, and
the mean PSA might have been higher in patients with PCa than in
those without PCa in the prior studies, indicating that the results
might have been statistically underrepresented.
The number of increases in the PSA level appears to be a useful
indicator for prostate biopsy. Marberger et al16 found that biopsy
based on a single increase in the PSA level was important for PCa
detection according to data from the Reduction by Dutasteride in
Prostate Cancer Events study.16 However, a recent review article
showed that biopsy based on an increase in the PSA level for a
patient using dutasteride may result in the exclusion of a sub-
stantial proportion of Gleason 7e10 cases (42.9%).17 The NCCN
guidelines recommend that patients with an initial negative biopsy
should undergo PSA assessments and DRE at 1-year intervals
initially. Therefore, we stratiﬁed the patients into two groups based
on the ﬁrst PSA pattern (increase/decrease) within 1 year after the
initial negative prostate biopsy, and we established a clinically
useful strategy according to the PSA pattern.
To increase the detection rate for patients to plan a repeat bi-
opsy, several strategies including extended biopsies, targeted bi-
opsy of mpMRI-suspicious areas, and transperineal saturation
biopsies, were suggested.18,19 mpMRI is recommended in men who
are candidates for repeat biopsy, the detection rate for PCa is be-
tween 39% and 59%, and the incidence of cancer located only in the
anterior zone is 20%.20e22 Although various biopsies protocol
before repeat prostate biopsy showed higher detection rate than
standard transrectal ultrasound (TRUS)-biopsy, mpMRI is not
reimbursed for patients suspected with PCa in Korea. Transperineal
saturation biopsies permit the operator easily to reach the anterior
zone of prostate the gland and lowering the risk of sepsis.23
Transperineal saturation biopsies are not generally considered
instead of TRUS-biopsy at our institutions. Biomarkers were rec-
ommended in patients who underwent at least one negative biopsy
for a repeat biopsy. The cost of the test remains a signiﬁcant barrier
to its utilization in most markets. Therefore, this study focused on
determining better indication and easier selection in patients using
further evaluation in the population of men with prior negative
biopsies and persistent suspicion of PCa.
The present study has several limitations. Multiple factors
inﬂuenced the clinical decision making regarding the imple-
mentation of a repeat biopsy, such as PSA and DRE. However,
several characteristics could account for the heterogeneity in the
results, including the multiple physicians and a patient preference.
Prostate Int 5 (2017) 24e2828The indication to repeat biopsy lacked standardization, and a se-
lection bias may have existed. Nevertheless, we believe that this
effect is inherent in any retrospective study and may reﬂect real-
world clinical practice in which the decision for repeat biopsy is
not standardized. Additionally, we were unaware of the number of
cases that were missed because of not recommending repeat bi-
opsy. Finally, this was a retrospective study, and the small number
of patients might have inﬂuenced the results. Further studies with a
larger number of patients are required to determine the detailed
clinical relevance of our ﬁndings in order to help reduce the
number of unnecessary biopsies.
5. Conclusion
The indications for a second prostate biopsy are a low prostate
volume and high number of increases in the PSA level among pa-
tients with a PSA decrease at the ﬁrst follow-up and a low prostate
volume and a high number of biopsy cores among patients with a
PSA increase at the ﬁrst follow-up.
Conﬂicts of interest
None.
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